Track the Cullinan Therapeutics, Inc. stock price and the full insider trade history of the company, a listed equity based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Market capitalisation: €1.3bn. The latest transaction was disclosed on 8 September 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Michaelson Jennifer. All data is openly available.
59
Insider Decl.
n/a
Thresholds
€6m
6 ops.
Buy Volume
€3m
34 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Cullinan Therapeutics, Inc. Strong Buy (bullish), based on 11 analysts. Average price target: US$32.36.
45Σ signal
Buys €6m€3m Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
1,345 shares@ US$10.011.2% of flowCommon StockSEC:0001193125-25-328909:0
25 of 59 declarations
Acerca de Cullinan Therapeutics, Inc.
Cullinan Therapeutics, Inc. es una empresa biofarmacéutica centrada en el desarrollo de terapias innovadoras para el tratamiento del cáncer. Se concentra en el descubrimiento y desarrollo de fármacos que se dirigen a mecanismos específicos de la enfermedad.